Delcath Systems Inc

DCTHNASDAQUSD
11.07 USD
0.39 (3.40%)AT CLOSE (11:59 AM EDT)
11.07
0.00 (0.00%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
11.07
0.00 (0.00%)
🔴Market: CLOSED
Open?$11.00
High?$11.32
Low?$10.87
Prev. Close?$11.46
Volume?550.6K
Avg. Volume?375.6K
VWAP?$11.12
Rel. Volume?1.47x
Bid / Ask
Bid?$9.64 × 100
Ask?$12.62 × 100
Spread?$2.98
Midpoint?$11.13
Valuation & Ratios
Market Cap?382.2M
Shares Out?34.5M
Float?25.4M
Float %?71.9%
P/E Ratio?681.20
P/B Ratio?3.39
EPS?$0.02
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Employees
156
Market Cap
382.2M
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Listed
2000-10-19
Address
566 QUEENSBURY AVENUE
QUEENSBURY, NY 12804
Phone: (518) 743-8892
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?11.24Strong
Quick Ratio?10.33Strong
Cash Ratio?3.86Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score
72/100
P/E?
681.2PRICEY
P/B?
3.39FAIR
P/S?
4.23FAIR
P/FCF?
19.9CHEAP
EV/EBITDA?
-257.8CHEAP
EV/Sales?
3.77FAIR
Returns & Efficiency
ROE?
0.5%WEAK
ROA?
0.4%WEAK
Cash Flow & Enterprise
FCF?$19.2M
Enterprise Value?$340.8M
Fundamentals ratios updated end of day